$7.82
0.38% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Amneal Pharmaceuticals, Inc. Class A Stock price

$7.82
-0.53 6.35% 1M
+1.40 21.81% 6M
+1.75 28.83% YTD
+1.61 25.93% 1Y
+2.73 53.63% 3Y
+3.31 73.39% 5Y
-7.19 47.90% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.03 0.38%
ISIN
US03168L1052
Symbol
AMRX
Sector
Industry

Key metrics

Market capitalization $2.42b
Enterprise Value $5.05b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 49.84
EV/Sales (TTM) EV/Sales 1.88
P/S ratio (TTM) P/S ratio 0.90
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 12.32%
Revenue (TTM) Revenue $2.68b
EBIT (operating result TTM) EBIT $344.21m
Free Cash Flow (TTM) Free Cash Flow $101.30m
Cash position $78.35m
EPS (TTM) EPS $-0.68
P/E forward 586.51
P/S forward 0.88
EV/Sales forward 1.83
Short interest 1.81%
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
75%
Hold
25%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,680 2,680
12% 12%
100%
- Direct Costs 1,697 1,697
11% 11%
63%
983 983
16% 16%
37%
- Selling and Administrative Expenses 230 230
22% 22%
9%
- Research and Development Expense 183 183
14% 14%
7%
571 571
13% 13%
21%
- Depreciation and Amortization 227 227
3% 3%
8%
EBIT (Operating Income) EBIT 344 344
27% 27%
13%
Net Profit -184 -184
1,887% 1,887%
-7%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
Business Wire
25 days ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conferences.
Neutral
Business Wire
about one month ago
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.
Neutral
Seeking Alpha
about 2 months ago
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Spec...
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 7,850
Founded 2002
Website www.amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today